BiotechTube
Avisi

Avisi

San Diego, United States· Est.
avisitech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Avisi Technologies is advancing a novel, nanotechnology-based implant called VisiPlate for the surgical treatment of open-angle glaucoma, the leading cause of irreversible blindness. The company's core innovation is an ultrathin, freestanding material fabricated using MEMS (Micro-Electro-Mechanical Systems) techniques, designed to facilitate controlled aqueous drainage with minimal foreign body response. Having secured $21.7M in total funding, including a recent $10.7M Series A round, Avisi is now conducting the pivotal SAPPHIRE clinical trial under an FDA Investigational Device Exemption (IDE). The company operates in a large and growing market with significant unmet need for more effective and tolerable surgical interventions.

OphthalmologyGlaucoma

Technology Platform

MEMS (Micro-Electro-Mechanical Systems) micro-fabrication platform for creating ultrathin, freestanding medical implants. Proprietary bilayer material of alumina and Parylene-C designed to minimize fibrosis.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The global glaucoma patient population is large and growing, with a significant unmet need for safer, more effective surgical options beyond medications and invasive traditional surgeries.
Avisi's ultrathin, nanotechnology-based VisiPlate targets the shortcomings of current drainage devices, positioning it to capture share in a multi-billion dollar surgical market.
Successful clinical validation could also establish their material platform for other ophthalmic or biomedical applications.

Risk Factors

The company faces high clinical and regulatory risk, as its entire value depends on the success of the single ongoing pivotal trial (SAPPHIRE).
Even with approval, commercial adoption by surgeons against entrenched competitors is a significant challenge.
As a pre-revenue company, it will require substantial additional capital to reach commercialization, posing financial and dilution risks.

Competitive Landscape

Avisi competes in the glaucoma surgical device market, which includes large players like Alcon (with the Ahmed and Molteno valves) and AbbVie's Allergan (formerly), as well as numerous companies in the MIGS (Minimally Invasive Glaucoma Surgery) segment such as Glaukos, iStent by Glaukos (now part of Alcon), and Hydrus Microstent by Alcon. VisiPlate's differentiation lies in its nanotechnology-driven, ultrathin, multichannel design aimed at reducing fibrosis, a key failure mode for competitors.

More companies in Small Molecule Drugs →More companies in United States →